CTLA-4, CD28, and ICOS gene polymorphism associations with non-small-cell lung cancer

Human Immunology

Volumn 72, Issue 10, 2011, Pages 947-954

  Karabon, Lidia ^a   Pawlak, Edyta ^a   Tomkiewicz, Anna ^a   Jedynak, Anna ^a   Passowicz Muszynska, Ewa ^b   Zajda, Katarzyna ^c   Jonkisz, Anna ^b   Jankowska, Renata ^b   Krzakowski, Maciej ^c   Frydecka, Irena ^a,b  

^a INSTITUTE OF IMMUNOLOGY AND EXPERIMENTAL THERAPY   (Poland)

^b WROCLAW MEDICAL UNIVERSITY   (Poland)

^c INSTITUTE OF ONCOLOGY   (Poland)

Author keywords

CD28; CTLA 4; ICOS; Non small cell lung cancer; Polymorphisms

Indexed keywords

CD28 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; INDUCIBLE COSTIMULATOR PROTEIN; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG;

ADULT; AGED; ALLELE; ANTIGEN PRESENTATION; ARTICLE; CANCER RISK; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE COURSE; FEMALE; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENETIC RISK; GENOTYPE; HAPLOTYPE; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; RISK ASSESSMENT; SEX DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; SURVIVAL RATE;

ADULT; AGED; AGED, 80 AND OVER; ALLELES; ANTIGENS, CD28; CARCINOMA, NON-SMALL-CELL LUNG; CASE-CONTROL STUDIES; CTLA-4 ANTIGEN; DISEASE PROGRESSION; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; INDUCIBLE T-CELL CO-STIMULATOR PROTEIN; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; POLAND; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS; SMOKING; SURVIVAL RATE;

EID: 80052964550     PISSN: 01988859     EISSN: 18791166     Source Type: Journal    
DOI: 10.1016/j.humimm.2011.05.010     Document Type: Article

References (44)

1. Landis S.H., Murray T., Bolden S., Wingo P.A. Cancer statistics, 1998. CA Cancer J Clin 1998, 48:6-29.
2. Allison J.P., Hurwitz A.A., Leach D.R. Manipulation of costimulatory signals to enhance antitumor T-cell responses. Curr Opin Immunol 1995, 7:682-686.
3. Frauwirth K.A., Thompson C.B. Activation and inhibition of lymphocytes by costimulation. J Clin Invest 2002, 109:295-299.
4. Carreno B.M., Collins M. The B7 family of ligands and its receptors: new pathways for costimulation and inhibition of immune responses. Annu Rev Immunol 2002, 20:29-53.
5. Frydecka I., Kosmaczewska A., Bocko D., Ciszak L., Wolowiec D., Kuliczkowski K., et al. Alterations of the expression of T-cell-related costimulatory CD28 and downregulatory CD152 (CTLA-4) molecules in patients with B-cell chronic lymphocytic leukaemia. Br J Cancer 2004, 90:2042-2048.
6. Melichar B., Nash M.A., Lenzi R., Platsoucas C.D., Freedman R.S. Expression of costimulatory molecules CD80 and CD86 and their receptors CD28, CTLA-4 on malignant ascites CD3+ tumour-infiltrating lymphocytes (TIL) from patients with ovarian and other types of peritoneal carcinomatosis. Clin Exp Immunol 2000, 119:19-27.
7. Hutloff A., Dittrich A.M., Beier K.C., Eljaschewitsch B., Kraft R., Anagnostopoulos I., et al. ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28. Nature 1999, 397:263-266.
8. + T cells. J Immunol 2000, 165:5035-5040.
9. Walunas T.L., Lenschow D.J., Bakker C.Y., Linsley P.S., Freeman G.J., Green J.M., et al. CTLA-4 can function as a negative regulator of T cell activation. Immunity 1994, 1:405-413.
10. Tivol E.A., Borriello F., Schweitzer A.N., Lynch W.P., Bluestone J.A., Sharpe A.H. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 1995, 3:541-547.
11. Leach D.R., Krummel M.F., Allison J.P. Enhancement of antitumor immunity by CTLA-4 blockade. Science 1996, 271:1734-1736.
12. Hurwitz A.A., Foster B.A., Kwon E.D., Truong T., Choi E.M., Greenberg N.M., et al. Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade. Cancer Res 2000, 60:2444-2448.
13. Maker A.V., Phan G.Q., Attia P., Yang J.C., Sherry R.M., Topalian S.L., et al. Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study. Ann Surg Oncol 2005, 12:1005-1016.
14. Phan G.Q., Yang J.C., Sherry R.M., Hwu P., Topalian S.L., Schwartzentruber D.J., et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci U S A 2003, 100:8372-8377.
15. O'Day S.J., Hamid O., Urba W.J. Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4): a novel strategy for the treatment of melanoma and other malignancies. Cancer 2007, 110:2614-2627.
16. Gough S.C., Walker L.S., Sansom D.M. CTLA4 gene polymorphism and autoimmunity. Immunol Rev 2005, 204:102-115.
17. Kristiansen O.P., Larsen Z.M., Pociot F. CTLA-4 in autoimmune diseases-a general susceptibility gene to autoimmunity?. Genes Immun 2000, 1:170-184.
18. Ghaderi A., Yeganeh F., Kalantari T., Talei A.R., Pezeshki A.M., Doroudchi M., et al. Cytotoxic T lymphocyte antigen-4 gene in breast cancer. Breast Cancer Res Treat 2004, 86:1-7.
19. Piras G., Monne M., Uras A., Palmas A., Murineddu M., Arru L., et al. Genetic analysis of the 2q33 region containing CD28-CTLA4-ICOS genes: association with non-Hodgkin's lymphoma. Br J Haematol 2005, 129:784-790.
20. Su T.H., Chang T.Y., Lee Y.J., Chen C.K., Liu H.F., Chu C.C., et al. CTLA-4 gene and susceptibility to human papillomavirus-16-associated cervical squamous cell carcinoma in Taiwanese women. Carcinogenesis 2007, 28:1237-1240.
21. Wong Y.K., Chang K.W., Cheng C.Y., Liu C.J. Association of CTLA-4 gene polymorphism with oral squamous cell carcinoma. J Oral Pathol Med 2006, 35:51-54.
22. Suwalska K., Pawlak E., Karabon L., Tomkiewicz A., Dobosz T., Urbaniak-Kujda D., et al. Association studies of CTLA-4, CD28, and ICOS gene polymorphisms with B-cell chronic lymphocytic leukemia in the Polish population. Hum Immunol 2008, 69:193-201.
23. Sun T., Zhou Y., Yang M., Hu Z., Tan W., Han X., et al. Functional genetic variations in cytotoxic T-lymphocyte antigen 4 and susceptibility to multiple types of cancer. Cancer Res 2008, 68:7025-7034.
24. Daroszewski J., Pawlak E., Karabon L., Frydecka I., Jonkisz A., Slowik M., et al. Soluble CTLA-4 receptor an immunological marker of Graves' disease and severity of ophthalmopathy is associated with CTLA-4 Jo31 and CT60 gene polymorphisms. Eur J Endocrinol 2009, 161:787-793.
25. Shi Y.Y., He L. SHEsis, a powerful software platform for analyses of linkage disequilibrium, haplotype construction, and genetic association at polymorphism loci. Cell Res 2005, 15:97-98.
26. Karabon L., Kosmaczewska A., Bilinska M., Pawlak E., Ciszak L., Jedynak A., et al. The CTLA-4 gene polymorphisms are associated with CTLA-4 protein expression levels in multiple sclerosis patients and with susceptibility to disease. Immunology 2009, 128:e787-e796.
27. Hadinia A., Hossieni S.V., Erfani N., Saberi-Firozi M., Fattahi M.J., Ghaderi A. CTLA-4 gene promoter and exon 1 polymorphisms in Iranian patients with gastric and colorectal cancers. J Gastroenterol Hepatol 2007, 22:2283-2287.
28. Pawlak E., Karabon L., Wlodarska-Polinska I., Jedynak A., Jonkisz A., Tomkiewicz A., et al. Influence of CTLA-4/CD28/ICOS gene polymorphisms on the susceptibility to cervical squamous cell carcinoma and stage of differentiation in the Polish population. Hum Immunol 2010, 71:195-200.
29. Thomas T.L., Doyle L.A., Edelman M.J. Lung cancer in women: emerging differences in epidemiology, biology, and therapy. Chest 2005, 128:370-381. Ref Type: Generic.
30. Dresler C.M., Fratelli C., Babb J., Everley L., Evans A.A., Clapper M.L. Gender differences in genetic susceptibility for lung cancer. Lung Cancer 2000, 30:153-160.
31. Kouki T., Sawai Y., Gardine C.A., Fisfalen M.E., Alegre M.L., DeGroot L.J. CTLA-4 gene polymorphism at position 49 in exon 1 reduces the inhibitory function of CTLA-4 and contributes to the pathogenesis of Graves' disease. J Immunol 2000, 165:6606-6611.
32. Anjos S., Nguyen A., Ounissi-Benkalha H., Tessier M.C., Polychronakos C. A common autoimmunity predisposing signal peptide variant of the cytotoxic T-lymphocyte antigen 4 results in inefficient glycosylation of the susceptibility allele. J Biol Chem 2002, 277:46478-46486.
33. Cozar J.M., Romero J.M., Aptsiauri N., Vazquez F., Vilchez J.R., Tallada M., et al. High incidence of CTLA-4 AA (CT60) polymorphism in renal cell cancer. Hum Immunol 2007, 68:698-704.
34. Cheng T.Y., Lin J.T., Chen L.T., Shun C.T., Wang H.P., Lin M.T., et al. Association of T-cell regulatory gene polymorphisms with susceptibility to gastric mucosa-associated lymphoid tissue lymphoma. J Clin Oncol 2006, 24:3483-3489.
35. Tomkiewicz A., Karabon L., Pawlak E., Jedynak A., Kielbinski M., Woszczyk D., et al. The autoimmune-associated alleles of CTLA-4 gene are also risk factors for development of multiple myeloma. Eur J Immunol 2009, 39:S447.
36. Solerio E., Tappero G., Iannace L., Matullo G., Ayoubi M., Parziale A., et al. CTLA4 gene polymorphism in Italian patients with colorectal adenoma and cancer. Dig Liver Dis 2005, 37:170-175.
37. Bouwhuis M.G., Gast A., Figl A., Eggermont A.M., Hemminki K., Schadendorf D., et al. Polymorphisms in the CD28/CTLA4/ICOS genes: role in malignant melanoma susceptibility and prognosis?. Cancer Immunol Immunother 2009, 59:303-312.
38. Welsh M.M., Applebaum K.M., Spencer S.K., Perry A.E., Karagas M.R., Nelson H.H. CTLA4 variants, UV-induced tolerance, and risk of non-melanoma skin cancer. Cancer Res 2009, 69:6158-6163.
39. Ligers A., Teleshova N., Masterman T., Huang W.X., Hillert J. CTLA-4 gene expression is influenced by promoter and exon 1 polymorphisms. Genes Immun 2001, 2:145-152.
40. Dilmec F., Ozgonul A., Uzunkoy A., Akkafa F. Investigation of CTLA-4 and CD28 gene polymorphisms in a group of Turkish patients with colorectal cancer. Int J Immunogenet 2008, 35:317-321.
41. Zheng C., Huang D., Liu L., Björkholm M., Holm G., Yi Q., et al. Cytotoxic T-lymphocyte antigen-4 microsatellite polymorphism is associated with multiple myeloma. Br J Haematol 2001, 112:216-218.
42. Haaning Andersen A.D., Lange M., Lillevang S.T. Allelic variation of the inducible costimulator (ICOS) gene: detection of polymorphisms, analysis of the promoter region, and extended haplotype estimation. Tissue Antigens 2003, 61:276-285.
43. Pravica V., Perrey C., Stevens A., Lee J.H., Hutchinson I.V. A single nucleotide polymorphism in the first intron of the human IFN-gamma gene: absolute correlation with a polymorphic CA microsatellite marker of high IFN-gamma production. Hum Immunol 2000, 61:863-866.
44. Arlinghaus R., Sun T. Signal transduction pathways in Bcr-Abl transformed cells. Cancer Treat Res 2004, 119:239-270.